#United States #Henderson #VolitionRx #Nu.Q® #sepsis test

VolitionRx's Innovative Finger-Prick Sepsis Test

In a groundbreaking development, VolitionRx Limited (NYSE AMERICAN: VNRX) has presented a revolutionary approach to diagnosing sepsis through a rapid, point-of-care finger-prick test. This new lateral flow prototype could drastically transform how sepsis is identified, particularly in critical care settings.

Key Features of the Test

The newly introduced finger-prick test is designed to work in conjunction with Volition's already established Nu.Q® NETs test, which is employed in centralized laboratory settings. Dr. Andrew Retter, a critical care lead and consultant at Volition, stated that this innovation represents a significant leap towards providing an easily accessible, cost-effective, and minimally invasive test option for sepsis.

This test's design allows for immediate application in various healthcare settings, including emergency rooms and bedside care, significantly expediting patient care processes. The finger-prick method is particularly beneficial in regions lacking advanced laboratory infrastructure, offering a promising solution in low-income countries.

Correlation with Established Testing Methods

Clinical trials have shown that the results from the lateral flow finger-prick tests have a high correlation with those from Volition's automated Nu.Q® NETs test, boasting a Spearman correlation of 0.85 and a Pearson correlation of 0.881. These statistics suggest that the new testing method could reliably measure nucleosome levels in sepsis patients at the point of care.

Dr. Retter emphasized the potential of this test to facilitate rapid clinical decision-making, ultimately improving patient outcomes. The ability to swiftly identify high-risk patients at the bedsides is a monumental step forward in the world of sepsis diagnosis. By quantifying nucleosome levels through a simple finger-prick, healthcare professionals can act quickly, tailoring interventions to the needs of critically ill patients.

Addressing a Global Health Crisis

With approximately 166 million cases of sepsis reported globally, this initiative tackles a significant public health issue. The World Health Organization highlights that sepsis represents a leading cause of mortality worldwide, accounting for more than 30% of all global deaths in 2021, with an alarming impact in lower-middle-income regions.

Dr. Gaetan Michel, COO of Volition, described the unique advantages of this technology in areas with unlikely access to comprehensive laboratory facilities, positing that it may pave the way for revolutionizing healthcare in underprivileged regions and thus create extensive market opportunities.

As the healthcare community increasingly recognizes the need for decentralized health solutions, VolitionRx aims to foster partnerships with NGOs and other organizations to implement this technology effectively in underserved markets.

Conclusion

VolitionRx's introduction of the lateral flow finger-prick test signifies a massive advancement in sepsis testing. Not only does it enhance immediate diagnostic capabilities, but it also opens doors for equitable access to crucial medical diagnostics, especially in areas that previously lacked such resources. This test represents a significant shift in how critical conditions like sepsis are approached within healthcare systems, demonstrating the immense potential of diagnostic technology to save lives and improve healthcare outcomes globally.